Maintenance bacillus calmette-guérin treatment of non-muscle-invasive bladder cancer: A critical evaluation of the evidence Review uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • BCG Vaccine
  • Urinary Bladder
  • Urinary Bladder Neoplasms

abstract

  • The optimal duration of BCG treatment in patients with NMIBC remains unknown and should be the subject of further studies. We recommend that in addition to 3 yr of maintenance BCG, guideline panels also include 1 yr of therapy and induction BCG with retreatment on recurrence as a possible treatment options for patients with NMIBC, albeit with a lower level of evidence and grade of recommendation.

publication date

  • October 2013

Research

keywords

  • Review

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.eururo.2013.05.027

PubMed ID

  • 23711538

Additional Document Info

start page

  • 579

end page

  • 85

volume

  • 64

number

  • 4